Cargando…

P-032: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE

Detalles Bibliográficos
Autores principales:	A., IDRIZOVIC, A., COLLADO GIMBERT, E., VAN BEERS, R., COLOMBATTI, P., BARTOLUCCI, M., DE MONTALEMBERT, M., BOARO, D., BENEITEZ, A., ORTUÑO, A., RUIZ, I., ISOLA, E., CELA, R., VAN WIJK, M., RAB, M., MAÑU PEREIRA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426826/ http://dx.doi.org/10.1097/01.HS9.0000873024.82912.2d

Ejemplares similares

P1478: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE
por: Idrizovic, A., et al.
Publicado: (2022)

Challenges and Opportunities of Precision Medicine in Sickle Cell Disease: Novel European Approach by GenoMed4All Consortium and ERN-EuroBloodNet
por: Collado, Anna, et al.
Publicado: (2023)

P1500: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
por: van der Veen, S., et al.
Publicado: (2022)

O-02: RADIOMICS AND ARTIFICIAL INTELLIGENCE FOR IDENTIFICATION AND MONITORING OF SILENT CEREBRAL INFARCTS IN SICKLE CELL DISEASE: FIRST ANALYSIS FROM THE GENOMED4ALL EUROPEAN PROJECT
por: R., BIONDI, et al.
Publicado: (2022)

P-023: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
por: S., VAN DER VEEN, et al.
Publicado: (2022)

Comment on: Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia
por: Sheehan, Vivien A., et al.
Publicado: (2022)

5610325 VARIABILITY OF OXYGENSCAN PARAMETERS ACCORDING TO THE TYPE OF THERAPY IN CHILDREN WITH SICKLE CELL DISEASE: PRELIMINARY DATA FROM A FEASIBILITY STUDY
por: Reggiani, G., et al.
Publicado: (2023)

Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients
por: Rab, Minke A.E., et al.
Publicado: (2019)

PB2518: OPTIMIZING THE DETECTION OF 2,3- DIPHOSPHOGLYCERATE IN DRIED BLOOD SPOTS OF PATIENTS WITH SICKLE CELL DISEASE: UNTARGETED METABOLOMICS WITHIN THE GENOMED4ALL PROJECT
por: van der Veen, Sigrid, et al.
Publicado: (2023)

PI-04: OXYGEN GRADIENT EKTACYTOMETRY-DERIVED BIOMARKERS ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE COMPLICATIONS IN SICKLE CELL DISEASE
por: M., RAB, et al.
Publicado: (2022)

P1492: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
por: Rab, M., et al.
Publicado: (2022)

PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
por: M., RAB, et al.
Publicado: (2022)

Methodological aspects of the oxygenscan in sickle cell disease: A need for standardization
por: Rab, Minke A.E., et al.
Publicado: (2019)

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: M., VAN DIJK, et al.
Publicado: (2022)

Editorial for Special Issue “Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies”
por: Colombatti, Raffaella, et al.
Publicado: (2019)

Newborn Screening for Sickle Cell Disease in Europe
por: Daniel, Yvonne, et al.
Publicado: (2019)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M. J., et al.
Publicado: (2022)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M.J., et al.
Publicado: (2023)

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Osunkwo, I, et al.
Publicado: (2022)

P-010: TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HEALTHCARE PROFESSIONAL (HCP)–PATIENT RELATIONSHIP: HCP OPINIONS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: B., ANDEMARIAM, et al.
Publicado: (2022)

Sickle cell disease: embedding patient participation into an international conference can transform the role of lived experience
por: Pellegrini, Mariangela, et al.
Publicado: (2023)

Top Physics at ATLAS 032
por: Stavropoulos, G D
Publicado: (2004)

Shower Production by Highly Energetic Muons 032
por: Kortner, O, et al.
Publicado: (2002)

P1467: HEALTHCARE PROFESSIONALS (HCP) OPINIONS ON TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HCP–PATIENT RELATIONSHIP: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Andemariam, B., et al.
Publicado: (2022)

P02-032 - CAPS: a novel mutation and an unusual phenotype
por: Insalaco, A, et al.
Publicado: (2013)

Effects of Genotypes and Treatment on Oxygenscan Parameters in Sickle Cell Disease
por: Boisson, Camille, et al.
Publicado: (2021)

Opération piquet PO 2000-032
por: Royer, J P
Publicado: (2000)

P01-032 – Characterization of genetic-negative FMF
por: Ben-Zvi, I, et al.
Publicado: (2013)

A032 LATINOS EXPERIENCE LONGER DURATION OF UNCONTROLLED ASTHMA AFTER COVID INFECTION
por: Foster, K., et al.
Publicado: (2021)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
por: Traets, Marissa, et al.
Publicado: (2023)

5613081 GAPS IN DATA ON GLOBAL PREVALENCE AND BIRTH PREVALENCE OF SICKLE CELL DISEASE AND SICKLE CELL TRAIT: CALL FOR ACTION TO SCALE UP AND HARMONIZE DATA COLLECTION
por: Colombatti, R., et al.
Publicado: (2023)

Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease
por: Rab, Minke A. E., et al.
Publicado: (2020)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
por: van Dijk, Myrthe, et al.
Publicado: (2023)

PB2215: GLOBAL EPIDEMIOLOGY OF SICKLE CELL DISEASE: A SYSTEMATIC LITERATURE REVIEW
por: Colombatti, R., et al.
Publicado: (2022)

Understanding and Improving the Membrane Permeability of VH032-Based PROTACs
por: Klein, Victoria G., et al.
Publicado: (2020)

P032: Clostridium difficile infection in Tenerife Canary Island, Spain
por: Hernández, M, et al.
Publicado: (2013)

Title unknown, CERN-ALEPH-2000-032
por: CERN. Geneva. ALEPH
Publicado: (2000)

Title unknown, CERN-ALEPH-97-032
por: CERN. Geneva. ALEPH
Publicado: (1997)

PW03-032 – Periodic fevers in children
por: Harper, C, et al.
Publicado: (2013)

The complete methylome of Helicobacter pylori UM032
por: Lee, Woon Ching, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j00hdrdjrhnhpqtt387ebqqft8